Eric Sachetta Buys 7,000 Shares of Sensus Healthcare (NASDAQ:SRTS) Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta purchased 7,000 shares of the company’s stock in a transaction dated Friday, November 21st. The shares were purchased at an average price of $3.93 per share, for a total transaction of $27,510.00. Following the completion of the purchase, the director owned 140,113 shares of the company’s stock, valued at approximately $550,644.09. This trade represents a 5.26% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Eric Sachetta also recently made the following trade(s):

• On Thursday, November 13th, Eric Sachetta acquired 2,500 shares of Sensus Healthcare stock. The stock was purchased at an average price of $4.50 per share, with a total value of $11,250.00.

Sensus Healthcare Trading Up 2.3%

Shares of SRTS opened at $4.02 on Friday. The stock’s 50 day moving average is $3.47 and its two-hundred day moving average is $4.06. Sensus Healthcare, Inc. has a twelve month low of $3.03 and a twelve month high of $9.33. The firm has a market capitalization of $66.03 million, a PE ratio of -67.00 and a beta of 1.38.

Sensus Healthcare (NASDAQ:SRTS) last issued its earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.06. The business had revenue of $6.88 million during the quarter, compared to the consensus estimate of $6.31 million. Sensus Healthcare had a negative return on equity of 1.58% and a negative net margin of 2.26%. On average, sell-side analysts predict that Sensus Healthcare, Inc. will post 0.32 EPS for the current year.

Institutional Trading of Sensus Healthcare

Several institutional investors and hedge funds have recently modified their holdings of SRTS. Vise Technologies Inc. acquired a new stake in shares of Sensus Healthcare in the second quarter valued at approximately $52,000. IFP Advisors Inc lifted its stake in Sensus Healthcare by 37.2% in the 1st quarter. IFP Advisors Inc now owns 18,800 shares of the company’s stock valued at $89,000 after buying an additional 5,100 shares in the last quarter. Trexquant Investment LP acquired a new stake in Sensus Healthcare during the 1st quarter valued at $93,000. American Century Companies Inc. increased its position in Sensus Healthcare by 12.7% during the first quarter. American Century Companies Inc. now owns 22,440 shares of the company’s stock worth $106,000 after buying an additional 2,520 shares in the last quarter. Finally, Chapin Davis Inc. raised its holdings in shares of Sensus Healthcare by 66.7% in the second quarter. Chapin Davis Inc. now owns 25,000 shares of the company’s stock worth $118,000 after acquiring an additional 10,000 shares during the last quarter. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Wall Street Analyst Weigh In

SRTS has been the subject of a number of recent analyst reports. HC Wainwright reduced their target price on Sensus Healthcare from $12.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, August 12th. Lake Street Capital reduced their price objective on shares of Sensus Healthcare from $13.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Weiss Ratings reissued a “sell (d)” rating on shares of Sensus Healthcare in a report on Wednesday, October 8th. Wall Street Zen cut shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Zacks Research raised Sensus Healthcare from a “strong sell” rating to a “hold” rating in a research note on Wednesday, October 22nd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.00.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.